Literature DB >> 8576319

Evidence for IgG autoantibodies to galectin-3, a beta-galactoside-binding lectin (Mac-2, epsilon binding protein, or carbohydrate binding protein 35) in human serum.

K P Mathews1, K N Konstantinov, I Kuwabara, P N Hill, D K Hsu, B L Zuraw, F T Liu.   

Abstract

Galectin-3 is a beta-galactoside-binding animal lectin formerly called epsilon protein, Mac-2, carbohydrate binding protein 35, CBH 30, L-29, or L34. The possible occurrence of autoantibodies to galectin-3 was investigated because crosslinking of galectins bound to IgE or Fc epsilon RI might produce mediator release from mast cells or basophils. Unexpectedly, a control serum from an individual free of current allergic symptoms was found to have a significantly elevated level of IgG anti-galectin-3 by ELISA employing galectin-3-coated wells incubated with test serum followed by HRPO-conjugated goat anti-human IgG. The reaction was not inhibitable by lactose, suggesting that it is not a result of binding of IgG by galectin-3 through lectin-carbohydrate interactions. The antibody activity was specifically adsorbed by galectin-3 and protein A-conjugated Sepharose and was associated primarily with subclass IgG1. The presence of the antibodies was confirmed by immunoblotting showing binding of IgG to the 30-kD galectin-3 band. The relevant epitopes were in the galectin-3 N-terminal domain. The propositus was subsequently found to have adenocarcinoma of the colon, and titers of IgG anti-galectin-3 were found to be sharply elevated after hemicolectomy. Similar antibody titers have not been found in family members, but small numbers of normal persons and patients with malignant neoplasms have been found to have evidence of IgG anti-galectin-3 antibodies at lower titers than the propositus. The pathogenesis of this autoimmune reaction is unclear, though there is a trend for it to occur in older persons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576319     DOI: 10.1007/bf01541323

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  31 in total

1.  Molecular cloning and chromosomal mapping of a human galactoside-binding protein.

Authors:  A Raz; P Carmi; T Raz; V Hogan; A Mohamed; S R Wolman
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

2.  Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein.

Authors:  A Raz; G Pazerini; P Carmi
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

3.  Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin.

Authors:  D K Hsu; R I Zuberi; F T Liu
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

4.  Human IgE-binding protein: a soluble lectin exhibiting a highly conserved interspecies sequence and differential recognition of IgE glycoforms.

Authors:  M W Robertson; K Albrandt; D Keller; F T Liu
Journal:  Biochemistry       Date:  1990-09-04       Impact factor: 3.162

5.  Molecular cloning of a human macrophage lectin specific for galactose.

Authors:  B J Cherayil; S Chaitovitz; C Wong; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Endogenous lectins from cultured cells. Isolation and characterization of carbohydrate-binding proteins from 3T3 fibroblasts.

Authors:  C F Roff; J L Wang
Journal:  J Biol Chem       Date:  1983-09-10       Impact factor: 5.157

7.  The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2).

Authors:  H J Woo; L M Shaw; J M Messier; A M Mercurio
Journal:  J Biol Chem       Date:  1990-05-05       Impact factor: 5.157

8.  An endogenous lectin, galectin-3 (epsilon BP/Mac-2), potentiates IL-1 production by human monocytes.

Authors:  K C Jeng; L G Frigeri; F T Liu
Journal:  Immunol Lett       Date:  1994-10       Impact factor: 3.685

9.  Allelic loss of chromosome 18q and prognosis in colorectal cancer.

Authors:  J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

10.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

Authors:  R Lubin; B Schlichtholz; D Bengoufa; G Zalcman; J Trédaniel; A Hirsch; C Caron de Fromentel; C Preudhomme; P Fenaux; G Fournier; P Mangin; P Laurent-Puig; G Pelletier; M Schlumberger; F Desgrandchamps; A Le Duc; J P Peyrat; N Janin; B Bressac; T Soussi
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

View more
  6 in total

1.  Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

Authors:  Kosei Nakajima; Dhong Hyo Kho; Takashi Yanagawa; Yosuke Harazono; Victor Hogan; Wei Chen; Rouba Ali-Fehmi; Rohit Mehra; Avraham Raz
Journal:  Cancer Res       Date:  2016-02-02       Impact factor: 12.701

2.  Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries.

Authors:  E Jensen-Jarolim; C Neumann; G Oberhuber; R Gscheidlinger; C Neuchrist; W Reinisch; R I Zuberi; E Penner; F T Liu; G Boltz-Nitulescu
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

3.  Natural autoantibody to galectin-9 in normal human sera.

Authors:  K Suk; D Y Hwang; M S Lee
Journal:  J Clin Immunol       Date:  1999-05       Impact factor: 8.317

4.  Anti-galectin-1 autoantibodies in human Trypanosoma cruzi infection: differential expression of this beta-galactoside-binding protein in cardiac Chagas' disease.

Authors:  L Giordanengo; S Gea; G Barbieri; G A Rabinovich
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

5.  The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.

Authors:  Kosei Nakajima; Lance K Heilbrun; Daryn Smith; Victor Hogan; Avraham Raz; Elisabeth Heath
Journal:  Oncotarget       Date:  2017-03-14

Review 6.  Galectin-3: an immune checkpoint target for musculoskeletal tumor patients.

Authors:  Kosei Nakajima; Vitaly Balan; Avraham Raz
Journal:  Cancer Metastasis Rev       Date:  2020-09-14       Impact factor: 9.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.